0000950159-23-000272.txt : 20231102 0000950159-23-000272.hdr.sgml : 20231102 20231102061618 ACCESSION NUMBER: 0000950159-23-000272 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231102 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Group CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 231369902 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Cigna Corp DATE OF NAME CHANGE: 20181221 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 cigna8k.htm THE CIGNA GROUP FORM 8-K
false 0001739940 0001739940 2023-11-02 2023-11-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

 

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 2, 2023

 

The Cigna Group
 

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of

 

incorporation)

 001-38769
(Commission File Number)		 82-4991898
(IRS Employer
Identification No.)

 

900 Cottage Grove Road

Bloomfield, Connecticut 06002

 

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code:

 

(860) 226-6000

 

Not Applicable

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

  Item 2.02 Results of Operations and Financial Condition.

 

On November 2, 2023, The Cigna Group issued a press release announcing results for the three months ended September 30, 2023. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report on Form 8-K, except as shall be expressly set forth by specific reference in such a filing.

 

 

  Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

  

Exhibit No. Description

 

 

  99.1 Press release dated November 2, 2023.

 

  104 Cover Page Interactive Data File (embedded within the Inline XBRL).

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  THE CIGNA GROUP
   
Date:  November 2, 2023 By: /s/ Brian C. Evanko       
    Brian C. Evanko
    Executive Vice President and Chief Financial Officer

  

 EX-99.1 2 ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Press Release

 

 

 

INVESTOR RELATIONS CONTACT:

Ralph Giacobbe

860-787-7968

Ralph.Giacobbe@TheCignaGroup.com

 

MEDIA CONTACT:

Justine Sessions

860-810-6523

Justine.Sessions@cigna.com

 

 

The Cigna Group Reports Strong Third Quarter 2023 Results,

Raises 2023 Adjusted EPS, Revenue, and Cash Flow Outlook

 

•Total revenues in the third quarter were $49.0 billion
•Shareholders’ net income for the third quarter was $1.4 billion, or $4.74 per share
•Adjusted income from operations1 for the third quarter was $2.0 billion, or $6.77 per share
•2023 outlook2 for adjusted income from operations1,2 increased to at least $24.75 per share2

 

BLOOMFIELD, CT, November 2, 2023 – Global health company The Cigna Group (NYSE: CI) today reported strong third quarter results reflecting revenue and earnings growth across its diversified portfolio of businesses.

 

“We continued to drive growth in the third quarter by harnessing our deep clinical expertise and service capabilities across our company, supporting high-quality care, improved affordability and better outcomes,” said David M. Cordani, chairman and chief executive officer. “With disciplined execution and continued innovation across Evernorth Health Services and Cigna Healthcare, we’re meeting the evolving needs of those we serve.”

 

Shareholders’ net income for the third quarter 2023 was $1.4 billion, or $4.74 per share, compared with $2.8 billion, or $8.97 per share, for the third quarter 20223, which included an after-tax gain of $1.4 billion, or $4.52 per share, from the Chubb Transaction4.

 

The Cigna Group's adjusted income from operations1 for the third quarter 2023 was $2.0 billion, or $6.77 per share, compared with $1.9 billion, or $6.05 per share, for the third quarter 20223, reflecting strong contributions from both Evernorth Health Services and Cigna Healthcare.

 

A reconciliation of shareholders’ net income to adjusted income from operations1 is provided on the following page and on Exhibit 1 of this earnings release.

 
2 

 

CONSOLIDATED HIGHLIGHTS

 

The following table includes highlights of results and reconciliations of total revenues to adjusted revenues5 and shareholders’ net income to adjusted income from operations1:

Consolidated Financial Results (dollars in millions):   
   Three Months Ended  Nine Months Ended
   September 30,  June 30,  September 30,
     2023    20223    2023    2023 
                     
Total Revenues  $49,048   $45,281   $48,586   $144,151 
Net Realized Investment Losses from Equity Method Investments5   30    80    30    22 
Adjusted Revenues5  $49,078   $45,361   $48,616   $144,173 
                     
Consolidated Earnings, net of taxes                    
Shareholders’ Net Income  $1,408   $2,757   $1,460   $4,135 
Net Realized Investment Losses1   41    145    9    56 
Amortization of Acquired Intangible Assets1   363    322    346    1,053 
Special Items1   199    (1,365)   5    205 
Adjusted Income from Operations1  $2,011   $1,859   $1,820   $5,449 
                      
Shareholders’ Net Income, per share   $4.74   $8.97   $4.92   $13.89 
Adjusted Income from Operations1, per share  $6.77   $6.05   $6.13   $18.31 

 

 

•Total revenues and adjusted revenues5 for the third quarter 2023 each increased 8% from the third quarter 2022, reflecting strong growth across Evernorth Health Services and Cigna Healthcare.

 

•Shareholders’ net income for the third quarter 2023 was $1.4 billion, or $4.74 per share, compared with $2.8 billion, or $8.97 per share, for the third quarter 20223, which included an after-tax gain of $1.4 billion, or $4.52 per share, from the Chubb Transaction4.

 

•Adjusted income from operations1 for the third quarter 2023 increased 8% from the third quarter 2022, reflecting strong contributions from Evernorth Health Services and Cigna Healthcare.

 

•The SG&A expense ratio6 and adjusted SG&A expense ratio6 were 7.7% and 7.3%, respectively, for the third quarter 2023 compared to 7.0% and 6.9%, respectively, for the third quarter 2022, reflecting increased investments to support business growth and expand our capabilities.

 

•The debt-to-capitalization ratio was 40.5% at September 30, 2023 compared to 41.9% at June 30, 2023.

 

•Year to date through November 1, 2023, the Company repurchased 7.7 million shares of common stock for approximately $2.2 billion.

 

 
3 

 

CUSTOMER RELATIONSHIPS

 

The following table summarizes The Cigna Group’s medical customers and overall customer relationships:

 

Customer Relationships (in thousands):

 

 

 As of the Periods Ended
  September 30, June 30, December 31,
  2023 2022 2023 2022
         
Total Pharmacy Customers7 98,325 94,846 98,638 93,905
         
U.S. Commercial 16,009 14,761 15,999 14,852
U.S. Government 1,970 1,381 1,883 1,354
International Health 1,628 1,812 1,624 1,798
Total Medical Customers7 19,607 17,954 19,506 18,004
         
Behavioral Care 25,100 44,522 26,383 44,841
Dental 18,593 18,380 18,634 18,397
Medicare Part D 2,544 2,902 2,542 2,874
         
Total Customer Relationships7 164,169 178,604 165,703 178,021

 

 

•Total pharmacy customers7 at September 30, 2023 increased 5% from December 31, 2022 to 98.3 million due to new sales and the continued expansion of relationships.

 

•Total medical customers7 at September 30, 2023 grew 9% from December 31, 2022 to 19.6 million, an increase of 1.6 million customers, primarily driven by growth in U.S. Commercial fee-based customers as well as in Individual and Medicare Advantage customers.

 

•Customer relationships7 were impacted by the non-renewal of a supplemental behavioral coverage contract with New York Life, which was insignificant to total revenues and adjusted income from operations1. Excluding the impact of this contract7, behavioral care and total customer relationships7 at September 30, 2023 increased 2% and 4%, respectively, from December 31, 2022.

 

 
4 

 

HIGHLIGHTS OF SEGMENT RESULTS

 

See Exhibit 1 for a reconciliation of adjusted income (loss) from operations1 to shareholders’ net income.

 

Evernorth Health Services

 

This segment offers a broad range of coordinated and point solution health services and capabilities, as well as those from partners across the health care system, in Pharmacy Benefits, Home Delivery Pharmacy, Specialty Pharmacy, Distribution and Care Delivery and Management Solutions to health plans, employers, government organizations and health care providers.

 

Financial Results (dollars in millions):
   Three Months Ended  Nine Months Ended
   September 30,  June 30,  September 30,
   2023  2022  2023  2023
             
Adjusted Revenues5  $38,596   $35,698   $38,205   $112,980 
Adjusted Income from Operations, Pre-Tax1  $1,716   $1,625   $1,516   $4,552 
Adjusted Margin, Pre-Tax8   4.4%    4.6%    4.0%    4.0% 

 

•Third quarter 2023 adjusted revenues5 increased 8% relative to third quarter 2022, reflecting strong organic growth in specialty and care delivery and management solutions.

 

•Third quarter 2023 adjusted income from operations, pre-tax1, increased 6% relative to third quarter 2022, reflecting growth in specialty and continued affordability improvements, partially offset by increased strategic investments in technology to support the onboarding of new clients and continued advancement of our digital capabilities and care solutions.

 

•Third quarter 2023 adjusted margin, pre-tax8, was 4.4% compared to 4.6% for third quarter 2022, reflecting continued strategic investments in technology to support the onboarding of new clients and expansion of existing client relationships.

 

 
5 

 

Cigna Healthcare

 

This segment includes U.S. Commercial, U.S. Government and International Health businesses, which provide comprehensive medical benefits and coordinated solutions to clients and customers. U.S. Commercial products and services include medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured clients. U.S. Government solutions include Medicare Advantage, Medicare Supplement and Medicare Part D plans for seniors, and individual health insurance plans. International Health solutions include health care coverage in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations.

 

Financial Results (dollars in millions):
   Three Months Ended  Nine Months Ended
   September 30,  June 30,  September 30,
     2023    20223    2023    2023 
                      
Adjusted Revenues5,9  $12,768   $11,177   $12,714   $38,200 
Adjusted Income from Operations, Pre-Tax1  $1,222   $1,050   $1,172   $3,509 
Adjusted Margin, Pre-Tax8   9.6%    9.4%    9.2%    9.2% 

 

•Third quarter 2023 adjusted revenues5,9 grew 14% over third quarter 2022, reflecting customer growth and premium rate increases to cover underlying medical cost trends.

 

•Third quarter 2023 adjusted income from operations, pre-tax1 increased 16% relative to third quarter 2022, primarily driven by a lower U.S. Commercial MCR6 and higher net investment income.

 

•The Cigna Healthcare MCR6 was 80.5% for third quarter 2023 compared to 80.8% for third quarter 2022, reflecting continued strong performance in our U.S. Commercial business driven by affordability initiatives and effective pricing execution, partially offset by business mix, reflecting higher customer growth in U.S. Government.

 

•Cigna Healthcare net medical costs payable10 was $5.09 billion at September 30, 2023, $4.05 billion at September 30, 2022, and $3.96 billion at December 31, 2022. The increases are primarily driven by customer growth and business mix. Favorable prior year reserve development on a gross pre-tax basis was $237 million and $278 million for the nine months ended September 30, 2023 and September 30, 2022, respectively.

 

 

 

Corporate and Other Operations

 

Corporate reflects interest expense, amounts not allocated to operating segments and includes intersegment eliminations. Additionally, this discussion includes items reported in Other Operations, which is comprised of Corporate Owned Life Insurance (“COLI”) and the Company’s run-off operations.

 

Financial Results (dollars in millions):            
   Three Months Ended  Nine Months Ended
   September 30,  June 30,  September 30,
     2023    20223    2023    2023 
                      
Adjusted (Loss) from Operations, Pre-Tax1  $(409)  $(295)  $(394)  $(1,202)

 

•Third quarter 2023 adjusted loss from operations, pre-tax1, was $409 million compared to $295 million for third quarter 2022, primarily reflecting the impact of higher interest rates on interest expense and pension costs.

 

 
6 

 

 

2023 OUTLOOK2

 

The Cigna Group's outlook2 for full year 2023 adjusted revenues2,5 increased to at least $192.0 billion. The Cigna Group’s outlook2 for full year 2023 consolidated adjusted income from operations1,2 is at least $7.36 billion, or at least $24.75 per share2. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2023 dividends.

 

(dollars in millions, except where noted and per share amounts)  
2023 Consolidated Metrics

Projection for Full Year Ending

December 31, 2023

Change from

Prior Projection

Adjusted Revenues2,5 at least $192,000 +$2,000
Adjusted Income from Operations1,2 at least $7,360  
Adjusted Income from Operations, per share1,2 at least $24.75 +$0.05
Adjusted SG&A Expense Ratio2,6 ~7.4% +10 bps
Adjusted Effective Tax Rate2,11 20.5% to 21.0% -50 bps at the midpoint
Cash Flow from Operations2 at least $10,500 +$1,000
Weighted Average Shares Outstanding (millions)2 296 to 298 -1 at the midpoint
     
2023 Evernorth Metrics    
Adjusted Income from Operations, Pre-Tax1,2 at least $6,400  
     
2023 Cigna Healthcare Metrics    
Adjusted Income from Operations, Pre-Tax1,2 at least $4,425  
Medical Care Ratio2,6 81.5% to 82.0% -15 bps at the midpoint
Total Medical Customer Growth2,7 at least 1,600,000 +200,000

 

 
7 

 

The foregoing statements represent the Company’s current estimates of The Cigna Group's 2023 consolidated and segment adjusted income from operations1,2 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.

 

This quarterly earnings release and the Quarterly Financial Supplement are available on The Cigna Group’s website in the Investor Relations section (https://investors.thecignagroup.com/overview/default.aspx). Management will be hosting a conference call to review third quarter 2023 results and discuss full year 2023 outlook beginning today at 8:30 a.m. ET. A link to the conference call is available in the Investor Relations section of The Cigna Group's website located at https://investors.thecignagroup.com/events-and-presentations/default.aspx.

 

The call-in numbers for the conference call are as follows:

Live Call

(888) 566-1889 (Domestic)

(773) 799-3989 (International)

Passcode: 11022023

 

Replay

(800) 839-1171 (Domestic)

(203) 369-3030 (International)

 

It is strongly suggested you dial in to the conference call by 8:15 a.m. ET.

 

 

About The Cigna Group

 

The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Evernorth Health Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has approximately 165 million customer relationships around the world. Learn more at thecignagroup.com.

 

 

Notes:

 

  1. Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the underlying results of operations of the Company’s businesses and permits analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income from operations is defined as shareholders’ net income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and special items. The Cigna Group’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income. See Exhibit 1 for a reconciliation of consolidated adjusted income from operations to shareholders’ net income.

 

 
8 

 

 

 

  1. Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income (loss) or adjusted revenues to total revenues on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof including (i) future net realized investment results (from equity method investments with respect to adjusted revenues) and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond The Cigna Group’s control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.

 

The Company’s outlook excludes the potential effects of any other business combinations that may occur after the date of this earnings release. The Company’s outlook includes the potential effects of expected future share repurchases and anticipated 2023 dividends.

 

As announced in January 2021, The Cigna Group currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board’s determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company’s financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.

 

The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.

 

  1. Effective January 1, 2023, The Cigna Group adopted ASU 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts, and related amendments. Prior year results have been restated to reflect the adoption of the new accounting guidance.

 

  1. On July 1, 2022, the Company completed the sale of its life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) to Chubb INA Holdings, Inc. ("Chubb") for approximately $5.4 billion in cash (the "Chubb transaction"). In December 2022, the Company divested its ownership interest in a joint venture in Türkiye.

 

  1. Adjusted revenues is used by The Cigna Group’s management because it permits analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a reconciliation of consolidated adjusted revenues to total revenues.

 

  1. Operating ratios are defined as follows:
•The Cigna Healthcare medical care ratio (“MCR”) represents medical costs as a percentage of premiums for all U.S. Commercial risk products, including medical, pharmacy, dental, stop loss and behavioral products provided through guaranteed cost or experience-rated funding arrangements, as well as Medicare Advantage, Medicare Part D, Medicare Supplement, individual on and off-exchange products, and health care products within our International Health business, within the Cigna Healthcare segment.
•SG&A expense ratio on a GAAP basis for the third quarter 2023 represents enterprise selling, general and administrative expenses of $3,788 million as a percentage of Total revenue of $49.0 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the third quarter 2022 represents enterprise selling, general and administrative expenses of $3,151 million as a percentage of Total revenue of $45.3 billion at a consolidated level.

 

 
9 

 

 

 

•Adjusted SG&A expense ratio for the third quarter 2023 represents enterprise selling, general and administrative expenses of $3,574 million excluding special items of $214 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the third quarter 2022 represents enterprise selling, general and administrative expenses of $3,127 million excluding special items of $24 million as a percentage of adjusted revenue at a consolidated level.

 

  1. Customer relationships are defined as follows:
•Total medical customers includes individuals in the Cigna Healthcare segment who meet any one of the following criteria: are covered under a medical insurance policy, managed care arrangement, or service agreement issued by Cigna Healthcare; have access to Cigna Healthcare's provider network for covered services under their medical plan; or have medical claims and services that are administered by Cigna Healthcare.
•International Health medical customers excludes medical customers served by less than 100% owned subsidiaries, as well as certain customers served by our third-party administrator. International Health customers as of September 30, 2023 reflect the transition of certain runoff business to Other Operations beginning January 1, 2023.
•Effective January 1, 2023, total pharmacy customers have been updated to reflect customer filled prescriptions through Inside Rx. Previously these customers had been estimated based on active customers over a period of time. Total pharmacy customers for prior periods have been restated to reflect this change.
•Behavioral care and total customer relationships as of December 31, 2022 excluding the impact of the supplemental behavioral coverage contract with New York Life were 24,696 thousand and 157,876 thousand, respectively.

 

  1. Adjusted margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment.

 

  1. The Cigna Group owns noncontrolling interests in certain operating joint ventures. As such, the adjusted revenues for the Cigna Healthcare segment only include the Company’s share of the joint ventures’ earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP.

 

  1. Medical costs payable within the Cigna Healthcare segment are presented net of reinsurance and other recoverables. The gross medical costs payable balance was $5.32 billion as of September 30, 2023, $4.18 billion as of December 31, 2022, and $4.25 billion as of September 30, 2022.

 

  1. The measure “adjusted effective tax rate” is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, “consolidated effective tax rate”. We define adjusted effective tax rate as the consolidated income tax rate applicable to the Company’s pre-tax income excluding pre-tax income (loss) attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Management is not able to provide a reconciliation to the consolidated effective tax rate on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof include (i) future net realized investment results and (ii) future special items.
 
10 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income from operations outlook for 2023 on a consolidated, per share, and segment basis; projected adjusted revenue outlook for 2023; projected total medical customer growth over year end 2022; projected medical care and adjusted SG&A expense ratios; projected consolidated adjusted effective tax rate; projected cash flow from operations; future dividends; projected weighted average shares outstanding; future financial or operating performance, including our ability to deliver affordable, predictable and simple solutions for our customers and clients; future growth, business strategy and strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas and the impact of the developing inflationary and interest rate pressures; capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; the impact of revised accounting rules related to accounting for long-duration contracts; and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of potential cyberattack or other privacy or data security incidents; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of http://www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

 

 

 

THE CIGNA GROUP  Exhibit 1
COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited)      
                         
      Three Months Ended     Nine Months Ended  Three Months Ended
      September 30,     September 30,  June 30,
(Dollars in millions, except per share amounts)     2023     2022 (1)     2023     2022 (1)  2023
                               
REVENUES                                                  
                                                   
Pharmacy revenues       $34,531        $32,762        $100,639        $95,431        $33,964 
Premiums        10,998         9,586         33,062         30,368         11,039 
Fees and other revenues        3,198         2,729         9,574         8,023         3,305 
Net investment income        321         204         876         943         278 
Total Revenues        49,048         45,281         144,151         134,765         48,586 
Net realized investment results from certain equity method investments        30         80         22         134         30 
Adjusted revenues (2)       $49,078        $45,361        $144,173        $134,899        $48,616 
                                                   
Shareholders' net income       $1,408        $2,757        $4,135        $5,511        $1,460 
Pre-tax adjusted income (loss) from operations by segment                                                  
Evernorth Health Services       $1,716        $1,625        $4,552        $4,402        $1,516 
Cigna Healthcare        1,222         1,050         3,509         3,582         1,172 
Corporate and Other Operations        (409)        (295)        (1,202)        (582)        (394)
Consolidated pre-tax adjusted income from operations        2,529         2,380         6,859         7,402         2,294 
Adjusted income tax expense        (518)        (521)        (1,410)        (1,622)        (474)
Consolidated after-tax adjusted income from operations       $2,011        $1,859        $5,449        $5,780        $1,820 
                                                   
Weighted average shares (in thousands)        297,131         307,517         297,663         315,647         296,879 
Common shares outstanding (in thousands)                            293,764         305,564         295,830 
SHAREHOLDERS' EQUITY at September 30,                           $45,691        $44,764           
SHAREHOLDERS' EQUITY PER SHARE at September 30,                           $155.54        $146.50           
                                                   
    Three Months Ended    Nine Months Ended    Three Months Ended 
    September 30,    September 30,    June 30, 
    2023    2022 (1)    2023    2022 (1)    2023 
(Dollars in millions, except per share amounts)   Pre-tax    After-tax    Pre-tax    After-tax    Pre-tax    After-tax    Pre-tax    After-tax    Pre-tax    After-tax 
                                                   
SHAREHOLDERS’ NET INCOME                                                  
                                                   
Shareholders' net income       $1,408        $2,757        $4,135        $5,511        $1,460 
Adjustments to reconcile adjusted income from operations                                                  
Net realized investment losses (3)  $44    41   $162    145   $66    56   $627    513   $4    9 
Amortization of acquired intangible assets   454    363    460    322    1,368    1,053    1,419    1,061    455    346 
Special Items                                                  
Charges (benefits) associated with litigation matters   201    171    —      —      201    171    (28)   (20)   —      —   
Loss (gain) on sale of businesses   21    19    (1,735)   (1,388)   21    19    (1,735)   (1,388)   —      —   
Integration and transaction-related costs   13    9    24    23    20    15    112    86    6    5 
Charge for organizational efficiency plan   —      —      —      —      —      —      22    17    —      —   
Adjusted income from operations (4)       $2,011        $1,859        $5,449        $5,780        $1,820 
                                                   
DILUTED EARNINGS PER SHARE                                                  
                                                   
Shareholders' net income       $4.74        $8.97        $13.89        $17.46        $4.92 
Adjustments to reconcile to adjusted income from operations                                                  
Net realized investment losses (3)  $0.15    0.14   $0.53    0.48   $0.22    0.19   $1.99    1.62   $0.01    0.03 
Amortization of acquired intangible assets   1.53    1.22    1.50    1.05    4.60    3.54    4.50    3.36    1.53    1.17 
Special Items                                                  
Charges (benefits) associated with litigation matters   0.68    0.58    —      —      0.67    0.58    (0.09)   (0.06)   —      —   
Loss (gain) on sale of businesses   0.07    0.06    (5.64)   (4.52)   0.07    0.06    (5.49)   (4.39)   —      —   
Integration and transaction-related costs   0.04    0.03    0.08    0.07    0.07    0.05    0.35    0.27    0.02    0.01 
Charge for organizational efficiency plan   —      —      —      —      —      —      0.07    0.05    —      —   
Adjusted income from operations (4)       $6.77        $6.05        $18.31        $18.31        $6.13 

(1) Effective January 1, 2023, The Cigna Group adopted ASU 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts, and related amendments. Prior year results have been restated to reflect the adoption of the new accounting guidance. Please refer to the Summary of Significant Accounting Policies footnote in The Cigna Group’s Form 10-Q for the period ended September 30, 2023, expected to be filed on November 2, 2023, for additional details.

(2) Adjusted revenues is defined as total revenues excluding the following adjustments: special items and The Cigna Group’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they are not indicative of past or future underlying performance of our businesses.

(3) Includes The Cigna Group’s share of certain realized investments results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.

(4) Adjusted income (loss) from operations is defined as shareholders’ net income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net realized investment results, amortization of acquired intangible assets and special items. The Cigna Group’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded.

 

 

 

 EX-101.SCH 3 ci-20231102.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ci-20231102_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ci-20231102_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 02, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 02, 2023
Entity File Number 001-38769
Entity Registrant Name The Cigna Group
Entity Central Index Key 0001739940
Entity Tax Identification Number 82-4991898
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 900 Cottage Grove Road
Entity Address, City or Town Bloomfield
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06002
City Area Code 860
Local Phone Number 226-6000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.01
Trading Symbol CI
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 8 cigna8k_htm.xml IDEA: XBRL DOCUMENT 0001739940 2023-11-02 2023-11-02 iso4217:USD shares iso4217:USD shares false 0001739940 8-K 2023-11-02 The Cigna Group DE 001-38769 82-4991898 900 Cottage Grove Road Bloomfield CT 06002 860 226-6000 false false false false Common Stock, Par Value $0.01 CI NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / M " 440 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " (,F)7)!Z;HJT M #X 0 &@ @ &E$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " (,F)799!YDAD! #/ P $P M@ &*$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #4$P " ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://thecignagroup.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ci-20231102.xsd ci-20231102_lab.xml ci-20231102_pre.xml cigna8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "cigna8k.htm": { "nsprefix": "CI", "nsuri": "http://thecignagroup.com/20231102", "dts": { "schema": { "local": [ "ci-20231102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ci-20231102_lab.xml" ] }, "presentationLink": { "local": [ "ci-20231102_pre.xml" ] }, "inline": { "local": [ "cigna8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://thecignagroup.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cigna8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "cigna8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://thecignagroup.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0000950159-23-000272-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950159-23-000272-xbrl.zip M4$L#!!0 ( @R8E=_6>W7* , .P+ / 8VDM,C R,S$Q,#(N>'-D MM5;;_:-UQL,+'!] M]?X=T$_G@VV#/L'4;X-;CNP!F_!+\ T&N T^8X8%5%Q<@Aⅅ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end